Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Melanoma
Interventions
DRUG

vemurafenib and cobimetinib

Comparison between different treatment regimens

Trial Locations (18)

Unknown

Hospital Universitario Donostia, Donostia / San Sebastian

Hospital General Universitario Santa Lucía, Cartagena

Hospital Clínic de Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria

Hospital Universitario Lucus Augusti, Lugo

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

Hospital Regional Universitario de Málaga, Málaga

Hospital Clínico Universitario de Salamanca, Salamanca

Hospital Universitario de Canarias, Santa Cruz de Tenerife

Hospital Universitario Virgen Macarena, Seville

Hospital General Universitario de Valencia, Valencia

Hospital Universitario Doctor Peset, Valencia

Hospital Universitario y Politécnico La Fe, Valencia

Hospital Álvaro Cunqueiro (Complejo Hospitalario Universitario de Vigo), Vigo

Hospital Universitario Miguel Servet, Zaragoza

All Listed Sponsors
collaborator

Roche Farma, S.A

INDUSTRY

collaborator

Pivotal S.L.

INDUSTRY

lead

Grupo Español Multidisciplinar de Melanoma

OTHER

NCT02583516 - Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma | Biotech Hunter | Biotech Hunter